Revolution Medicines draws $250M Tranche A loan after FDA approves RASONQUE for pancreatic cancer

Revolution Medicines, Inc.

• Tranche A Loan of $250.0M funded Oct 8, 2026, triggered by FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy.
• Interest at 3-month Term SOFR, floor of 3.50%, plus 5.75%, payable quarterly in arrears; interest-only with principal due Oct 8, 2032.
• Company paid Royalty Pharma a $5.0M draw fee; up to $500.0M more available under the $750.0M senior secured facility subject to milestones.
• Prepayment terms: make-whole plus 3.0% premium before the 2nd anniversary, 3.0% before the 3rd, and 1.0% thereafter.
• Company elected not to deliver a Tranche 3 Notice by the Oct 10, 2026 deadline, forgoing up to $250.0M and selling no incremental revenue participation right.